Table 4. List of prognostic markers responsible for poor outcome in stage II CRC patients.
| miRNA | N | Specimen Type | Dysregulation | Analysis Method | Reference |
|---|---|---|---|---|---|
| Tissue-based biomarker | |||||
| miR-320 | 37 (MSS) | Tissue | Down-regulated | qPCR | [26] |
| miR-498 | 37 (MSS) | Tissue | Down-regulated | qPCR | [26] |
| miR-21 | 42 | Tissue | Up-regulated | qPCR | [31,82] |
| miR-21 | 197 (Colon:130, Rectum:67) | Tissue (stroma) | Up-regulated | ISH | [233] |
| miR-29a | 59 | Tissue | Down-regulated | qPCR | [234] |
| miR-21 | 764 | Tissue | Up-regulated | ISH | [83] |
| miR-203 | 46 (African American) | Tissue | Up-regulated | qPCR | [235] |
| miR-20a, -21, -103a -106b, -143, -215 | 138 | Tissue | Up-regulated | Microarray, qPCR | [84] |
| miR-21 | 145 | Tissue | Up-regulated | qPCR | [158] |
| Blood-based biomarker | |||||
| miR-200c | 59 | Serum | Up-regulated | qPCR | [93] |
MSS; Microsatellite stable, qPCR; quantitative polymerase chain reaction, ISH; in situ hybridization